ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag controversy genetics genomics immunology

Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
Cannabinoid controversy
Tia Ghose | Sep 9, 2009 | 5 min read
Receptors that bind the active ingredient in marijuana may be novel therapeutic targets in autoimmune disease, but contested evidence for their presence on neurons could hamper drug development
3d rendered medically accurate illustration of a human embryo anatomy
The Ephemeral Life of the Placenta
Danielle Gerhard, PhD | Dec 4, 2023 | 10+ min read
Recent advances in modeling the human placenta, the least understood organ, may inform placental disorders like preeclampsia.
Drawn to Controversy
Megan Scudellari | Jan 1, 2014 | 8 min read
By digging through dusty storerooms and reading dead people’s mail, science historian and philosopher Michael Dietrich keeps biologists attuned to the past and mindful of the present.
Top 7 in Immunology
Edyta Zielinska | Aug 2, 2011 | 3 min read
A snapshot of the most highly ranked articles in microbiology and related areas, from Faculty of 1000
Top 7 in immunology
Edyta Zielinska | Feb 7, 2011 | 3 min read
A snapshot of the highest-F1000-ranked articles in immunology and related areas
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
3D illustration of a tapeworm infestation in a human intestine
Return of the Worms
Catherine Offord | Dec 1, 2021 | 10+ min read
Immunologists and parasitologists are working to revive the idea that helminths, and more specifically the molecules they secrete, could help treat allergies and autoimmune disease.

Run a Search

ADVERTISEMENT